Skip to main content
Erschienen in: CardioVasc 2/2023

31.03.2023 | Arterielle Hypertonie | Fortbildung

Interventionelle Therapie der arteriellen Hypertonie

Renale Denervation und Barorezeptor-Aktivierungstherapie

verfasst von: Dr. med. Raphael Schmieder

Erschienen in: CardioVasc | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Auszug

Dank mehrerer randomisierter und Scheinprozedur-kontrollierter Studien gibt es nun Evidenz zur antihypertensiven Effektivität der renalen Denervation. Momentan beschränkt sich der Einsatz auf die therapieresistente Hypertonie. Die Barorezeptor-Aktivierungstherapie zur Behandlung einer Hypertonie wird noch in Studien erprobt. …
Literatur
1.
Zurück zum Zitat GBD 2017 Risk Factor Collaborators. Lancet. 2018;392(10159):1923-94 GBD 2017 Risk Factor Collaborators. Lancet. 2018;392(10159):1923-94
2.
Zurück zum Zitat Neuhauser H et al. 12-Monats-Prävalenz von Bluthochdruck in Deutschland. Robert Koch-Institut, Epidemiologie und Gesundheitsberichterstattung; 2017 Neuhauser H et al. 12-Monats-Prävalenz von Bluthochdruck in Deutschland. Robert Koch-Institut, Epidemiologie und Gesundheitsberichterstattung; 2017
3.
Zurück zum Zitat Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67 Ettehad D et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67
4.
Zurück zum Zitat Muntner P et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324(12):1190-200 Muntner P et al. Trends in Blood Pressure Control Among US Adults With Hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324(12):1190-200
5.
Zurück zum Zitat Lechner K, Schunkert H. Personalized treatment concepts for arterial hypertension. Herz. 2021;46(1):91-104 Lechner K, Schunkert H. Personalized treatment concepts for arterial hypertension. Herz. 2021;46(1):91-104
6.
Zurück zum Zitat Noubiap JJ et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105 Noubiap JJ et al. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105
7.
Zurück zum Zitat Grassi G et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177(3):1020-5 Grassi G et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177(3):1020-5
8.
Zurück zum Zitat Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104 Williams B et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104
9.
Zurück zum Zitat Böhm M et al. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol. 2013;10(8):465-76 Böhm M et al. Renal sympathetic denervation: applications in hypertension and beyond. Nat Rev Cardiol. 2013;10(8):465-76
10.
Zurück zum Zitat Sakakura K et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-43 Sakakura K et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-43
11.
Zurück zum Zitat DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245-53 DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245-53
12.
Zurück zum Zitat DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75-197 DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75-197
13.
Zurück zum Zitat Schlaich MP et al. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012;14(3):247-53 Schlaich MP et al. Renal denervation in human hypertension: mechanisms, current findings, and future prospects. Curr Hypertens Rep. 2012;14(3):247-53
14.
Zurück zum Zitat Hering D et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457-64 Hering D et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension. 2013;61(2):457-64
15.
Zurück zum Zitat Krum H et al et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81 Krum H et al et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81
16.
Zurück zum Zitat Schlaich MP et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4 Schlaich MP et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4
17.
Zurück zum Zitat Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7.
18.
Zurück zum Zitat Esler MD et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82 Esler MD et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82
19.
Zurück zum Zitat Bhatt DL et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-401 Bhatt DL et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-401
20.
Zurück zum Zitat Kandzari DE et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219-27 Kandzari DE et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36(4):219-27
21.
Zurück zum Zitat Ott C, Schmieder RE. Renal Denervation for Resistant Hypertension: Past, Present, and Future. Curr Hypertens Rep. 2015;17(8):65 Ott C, Schmieder RE. Renal Denervation for Resistant Hypertension: Past, Present, and Future. Curr Hypertens Rep. 2015;17(8):65
22.
Zurück zum Zitat Mahfoud F et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219-27 Mahfoud F et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219-27
23.
Zurück zum Zitat Mahfoud F et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44):3272-81 Mahfoud F et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J. 2017;38(44):3272-81
24.
Zurück zum Zitat Mahfoud F et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41(16):1588-99 Mahfoud F et al. Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies. Eur Heart J. 2020;41(16):1588-99
25.
Zurück zum Zitat Townsend RR et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-70 Townsend RR et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-70
26.
Zurück zum Zitat Böhm M et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51 Böhm M et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51
27.
Zurück zum Zitat Azizi M et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-45 Azizi M et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391(10137):2335-45
28.
Zurück zum Zitat Azizi M et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-86 Azizi M et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476-86
29.
Zurück zum Zitat Kandzari DE et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-55 Kandzari DE et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346-55
30.
Zurück zum Zitat Mahfoud F et al. Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol. 2020;75(23):2879-88 Mahfoud F et al. Renal Denervation in High-Risk Patients With Hypertension. J Am Coll Cardiol. 2020;75(23):2879-88
31.
Zurück zum Zitat Schmieder RE et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-41 Schmieder RE et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-41
32.
Zurück zum Zitat Townsend RR et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16(1):89-96 Townsend RR et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16(1):89-96
33.
Zurück zum Zitat Sanders MF et al. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(9):1440-7 Sanders MF et al. Renal safety of catheter-based renal denervation: systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(9):1440-7
34.
Zurück zum Zitat Ott C et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33(6):1261-6 Ott C et al. Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. J Hypertens. 2015;33(6):1261-6
35.
Zurück zum Zitat Hering D et al. Effect of renal denervation on kidney function in patients with chronic kidney disease. Int J Cardiol. 2017;232:93-7 Hering D et al. Effect of renal denervation on kidney function in patients with chronic kidney disease. Int J Cardiol. 2017;232:93-7
36.
Zurück zum Zitat Barbato E et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023; https://doi.org/10.1093/eurheartj/ehad054 Barbato E et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023; https://​doi.​org/​10.​1093/​eurheartj/​ehad054
37.
Zurück zum Zitat Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42 Daugherty SL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42
38.
Zurück zum Zitat Gupta P et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69(6):1113-20 Gupta P et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69(6):1113-20
39.
Zurück zum Zitat Parati G et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705 Parati G et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021;77(2):692-705
40.
Zurück zum Zitat Schmieder RE et al. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331-42 Schmieder RE et al. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108(12):1331-42
41.
Zurück zum Zitat Mahfoud F et al. Kriterien der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von "Renale-Denervations-Zentren (RDZ)" - Update. Kardiologe. 2021;15(5):463-70 Mahfoud F et al. Kriterien der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von "Renale-Denervations-Zentren (RDZ)" - Update. Kardiologe. 2021;15(5):463-70
42.
Zurück zum Zitat McBryde FD et al. Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension. Auton Neurosci. 2017;204:126-30 McBryde FD et al. Evaluating the carotid bodies and renal nerves as therapeutic targets for hypertension. Auton Neurosci. 2017;204:126-30
43.
Zurück zum Zitat Illig KA et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44(6):1213-8 Illig KA et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006;44(6):1213-8
44.
Zurück zum Zitat Scheffers IJ et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254-8 Scheffers IJ et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254-8
45.
Zurück zum Zitat Bisognano JD et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73 Bisognano JD et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73
46.
Zurück zum Zitat Bakris GL et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152-8 Bakris GL et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152-8
47.
Zurück zum Zitat Hoppe UC et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270-6 Hoppe UC et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270-6
48.
Zurück zum Zitat Wallbach M et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;67(4):701-9 Wallbach M et al. Effects of Baroreflex Activation Therapy on Ambulatory Blood Pressure in Patients With Resistant Hypertension. Hypertension. 2016;67(4):701-9
49.
Zurück zum Zitat Halbach M et al. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension. J Hypertens. 2015;33(8):1697-703 Halbach M et al. Acute on/off effects and chronic blood pressure reduction after long-term baroreflex activation therapy in resistant hypertension. J Hypertens. 2015;33(8):1697-703
50.
Zurück zum Zitat Heusser K et al. Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients With Resistant Arterial Hypertension. Hypertension. 2016;67(3):585-91 Heusser K et al. Acute Response to Unilateral Unipolar Electrical Carotid Sinus Stimulation in Patients With Resistant Arterial Hypertension. Hypertension. 2016;67(3):585-91
Metadaten
Titel
Interventionelle Therapie der arteriellen Hypertonie
Renale Denervation und Barorezeptor-Aktivierungstherapie
verfasst von
Dr. med. Raphael Schmieder
Publikationsdatum
31.03.2023
Verlag
Springer Medizin
Erschienen in
CardioVasc / Ausgabe 2/2023
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI
https://doi.org/10.1007/s15027-023-2973-1

Weitere Artikel der Ausgabe 2/2023

CardioVasc 2/2023 Zur Ausgabe

Passend zum Thema

ANZEIGE

SGLT-2-Inhibitoren für alle Patient:innen mit chronischer Herzinsuffizienz empfohlen

Das ESC-Leitlinien-Update 2023 bedeutet einen Paradigmenwechsel in der Behandlung der Herzinsuffizienz (HF), denn nun werden SGLT-2i sowohl für HFrEF, als auch für HFmrEF und HFpEF empfohlen. Somit können jetzt alle Patient:innen mit HF von SGLT-2i als zentralem Bestandteil der Therapie profitieren.

ANZEIGE

Dapagliflozin als neue Therapieoption zur Behandlung einer Herzinsuffizienz unabhängig von der Ejektionsfraktion

Dapagliflozin ist nun zur Behandlung aller Patient:innen mit chronischer symptomatischer Herzinsuffizienz zugelassen und bietet somit auch neue Hoffnung für die Therapie von jenen mit HFpEF. In der DELIVER-Studie zeigte der SGLT-2-Inhibitor eine signifikante Reduktion von Herzinsuffizienz-Hospitalisierungen und CV-Todesfällen.

ANZEIGE

ACS-Erstlinientherapie: Konsensbeschluss rät zur DAPT mit Ticagrelor

Ein Konsortium führender Fachgesellschaften erarbeitete jüngst auf Basis umfangreicher Metaanalysen einen Konsens für die Therapie koronarer Herzkrankheiten. Was dabei auffiel: Die duale Plättchenhemmung (DAPT) mit Ticagrelor ist die bevorzugte Therapieoption für das akute Koronarsyndrom (ACS).